Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT07086976 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 18, 2025
- Completion date
- December 26, 2029
- Enrollment
- 90 (estimated)
- Sites
- 99
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune haemolytic anaemia